Rabies Vaccine Market Summary
According to a new report published by Allied Market Research, titled “Rabies Vaccine Market,” The rabies vaccine market size was valued at $1.3 billion in 2024 and is estimated to reach $2 billion by 2034, growing at a CAGR of 4.5% from 2025 to 2034.
Rise in prevalence of rabies, increase in post exposure prophylaxis for rabies and increase in number of initiatives by government for eradication rabies is anticipated to boost the growth of market. However, high cost of rabies vaccine is anticipated to hinder the growth of market. On the contrary, high presence of rabies vaccine providers, rise in number of adoptions of key strategies by manufacturers of rabies vaccine is to witness growth during the forecast period.
- Market Growth: The market is expected to grow from roughly $1.33 billion in 2024 to over $2 billion by 2034, driven by increased funding and adoption of advanced cell-culture technologies.
- Segment Growth: The Vero cell rabies vaccine segment dominates due to high immunogenicity and safety, while hospital-based demand is rising.
- Regional Analysis: North America holds the largest market share (approx. 40%), followed by Europe (30%) and Asia-Pacific (25%), the latter being driven by high incidences in India and China.
- Strategic Initiatives: The WHO’s “Zero by 30” campaign and Gavi’s financing of PEP in over 50 countries are significantly boosting demand.
Rabies is a zoonotic viral disease that causes encephalomyelitis in almost all warm-blooded animals, including humans. The causative agent is found in domestic and wild animals and is transmitted to other animals or humans through close contact with their saliva. The saliva is transmitted through bites, scratches, licks on broken skin, and mucous membranes. Rabies vaccine is an immunization used to prevent rabies in people who have been bitten by an animal or otherwise exposed to the rabies virus. Rabies vaccine is an inactivated virus vaccine prepared either in human diploid cell culture (HDCV) or in purified chick embryo cell culture (PCEC).
Request Sample of the Report on – https://www.alliedmarketresearch.com/request-sample/3264
The rabies vaccine market growth is driven by a rise in the prevalence of rabies, an increase in the number of stray dogs in developing countries such as India, and the presence of major market players who manufacture rabies vaccines. In addition, the provision of high-quality vaccines by major market players is anticipated to fuel the growth of the rabies vaccine market size. For instance, Sanofi S.A., a pharmaceutical company, provides Imovax rabies vaccine, which is a sterile, stable, freeze-dried suspension of rabies virus, which is used as pre-exposure prophylaxis and post-exposure prophylaxis. The vaccine is used for post-exposure immunization and post-exposure prophylaxis of rabies.
Segmental Overview
By product type
The chick embryo cells rabies vaccine segment held the highest market share in 2022, accounting for nearly two-fifth of the global rabies vaccine market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to the high presence of market players who manufactures chick embryo cells rabies vaccine. However, the human diploid cell vaccine segment is projected to manifest significant growth with a CAGR of 5.3% from 2023 to 2032, owing to the effectiveness and safety associated to human diploid cell vaccine.
By prophylaxis type
The post exposure prophylaxis segment held the highest market share in 2022, accounting for more than three-fifth of the global rabies vaccine market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to rise in awareness among population regarding post-exposure prophylaxis. However, the pre-exposure prophylaxis segment is projected to manifest a significant CAGR of 5.1% from 2023 to 2032, owing to rise in number of pre exposure prophylaxis by tourist, healthcare activist, environmentalist and population who are having pets.
By application
The human segment held the highest market share in 2022, accounting for more than three-fifth of the global rabies vaccine market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to rise in awareness among the population regarding importance of vaccination. However, the animal segment is projected to manifest a significant CAGR of 5.0% from 2023 to 2032.
By end user
The hospitals segment held the highest market share in 2022, accounting for more than two-fifth of the global rabies vaccine market revenue and is estimated to maintain its leadership status throughout the forecast period, owing to rise in number of vaccinations in hospitals. However, the veterinary clinics segment is projected to manifest a significant CAGR of 5.2% from 2023 to 2032.
Connect to our Analyst- https://www.alliedmarketresearch.com/connect-to-analyst/3264
By region
North America held the highest market share in terms of revenue in 2022, accounting for more than one-third of the global rabies vaccine market revenue. This is attributed to high presence of rabies vaccine manufacturers in North America and rising number of initiatives taken by government for animal vaccination. However, the Asia-Pacific region is expected to witness the fastest CAGR of 5.2% from 2023 to 2032 and is likely to dominate the market during the forecast period, owing to increase in awareness among the population regarding importance of rabies vaccination, rise in number of dog bites and increase in number of stray dogs in developing countries like India.
For Procurement Information- https://www.alliedmarketresearch.com/purchase-enquiry/3264
Leading Market Players:
- Bharat Biotech International Limited
- Sanofi
- Boehringer Ingelheim International Gmbh
- Novartis Ag
- Cadila Pharmaceuticals Ltd
- Merck And Co., Inc.
- Serum Institute of India Pvt. Ltd.
- Zoetis Inc.
- Elanco Animal Health Incorporated.
- Virbac Sa
Other Trending Reports in Life Science Domain-
Immune Checkpoint Inhibitors Market From USD 40.1 Billion in 2022 to USD 189.4 Billion by 2032
USD 12.3+ Bn Nerve Repair and Regeneration Market Value Cross by 2030 | Allied Market Research
Brachytherapy Market worth $1.6 billion by 2031 | CAGR of 7.1%
AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail themselves of an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Get access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients in making strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies, and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality data and help clients in every way possible to achieve success. Each data presented in the reports published by us is extracted through primary interviews with top officials from leading companies in the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int’l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Web: https://www.alliedmarketresearch.com
